Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Current Assets (2016 - 2025)

Corcept Therapeutics' Current Assets history spans 10 years, with the latest figure at $485.5 million for Q4 2025.

  • For Q4 2025, Current Assets rose 2.94% year-over-year to $485.5 million; the TTM value through Dec 2025 reached $485.5 million, up 2.94%, while the annual FY2025 figure was $485.5 million, 2.94% up from the prior year.
  • Current Assets for Q4 2025 was $485.5 million at Corcept Therapeutics, down from $541.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $541.1 million in Q3 2025 and bottomed at $266.5 million in Q4 2021.
  • The 5-year median for Current Assets is $443.1 million (2025), against an average of $445.0 million.
  • The largest annual shift saw Current Assets plummeted 44.31% in 2021 before it soared 87.36% in 2022.
  • A 5-year view of Current Assets shows it stood at $266.5 million in 2021, then skyrocketed by 87.36% to $499.3 million in 2022, then fell by 8.14% to $458.6 million in 2023, then increased by 2.83% to $471.6 million in 2024, then rose by 2.94% to $485.5 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Current Assets are $485.5 million (Q4 2025), $541.1 million (Q3 2025), and $443.1 million (Q2 2025).